Winner. Javier Pizones, MD, PhD, and his study, “Self-Perceived Health Status and Healthcare Consumption of Idiopathic Scoliosis Patients Treated More Than 20 Years Ago” will receive $450,000 in grant funding.
The 2022 Directed Research Grant cycle was designed as a retrospective, multi-center and preferably multi-continent study of a large cohort of patients diagnosed with Idiopathic Scoliosis in childhood and followed into adulthood. Applicants can receive up to $150,000 per year for three years.
The total for 2021 year's grant funding alone was more than $300,000 dedicated to spine research. All research grant applications are reviewed and selected by the SRS Research Grant Committee. For information on the SRS grant cycle, review our website.
Anyone interested in learning more about the SRS grant process is encouraged to watch the 2022 Grant Outcome Symposium, a free virtual event. In addition, an SRS Webinar for Professionals is scheduled for Saturday, April 23, 2022, on the topic “Parlaying Your SRS Grant into Big Funding: OREF, NIH, Shrine Grants and Beyond.” Click here to register.
Last September, the Society announced the first SRS research agenda identifying trending themes in spinal research and innovation that will influence fields of study for the coming three-to-five years. Setting this research agenda supports the overall SRS research mission to enhance the creation of meaningful discoveries for all patients with spinal deformity.
For more information on SRS Grant opportunities, visit our website. To contribute to grant research funding, review all the ways you can donate to SRS.
About Scoliosis Research Society
The Scoliosis Research Society is a non-profit, professional organization, made up of physicians and allied health personnel. Our primary focus is on providing continuing medical education for health care professionals and on funding/supporting research in spinal deformities. Founded in 1966, SRS has gained recognition as the world's premier spine deformity society. Please visit www.srs.org for further information. Also follow us on Twitter, Facebook and Instagram.